Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Immuron Limited ( (AU:IMC) ).
Immuron Limited announced that CEO Steven Lydeamore delivered a virtual presentation at the Emerging Growth Conference, highlighting the company’s orally delivered antibody platform and its portfolio of gastrointestinal-focused products. The appearance underscores Immuron’s efforts to raise its profile among growth-oriented investors as it advances its commercial product Travelan for travelers’ diarrhea, progresses IMM-529 as an adjunctive therapy for recurrent C. difficile infection with promising pre-clinical data, and expands its presence in functional gut health through the distribution of ProIBS, positioning the company as a niche player in oral immunotherapy and gastrointestinal therapeutics.
The most recent analyst rating on (AU:IMC) stock is a Sell with a A$0.04 price target. To see the full list of analyst forecasts on Immuron Limited stock, see the AU:IMC Stock Forecast page.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company specializing in the development and commercialization of orally delivered, targeted polyclonal antibodies for infectious diseases. Its lead product, Travelan, is an oral passive immunotherapy designed to reduce the risk of travelers’ diarrhea and related gastrointestinal disorders, marketed as a listed medicine in Australia, a licensed natural health product in Canada, and a dietary supplement in the U.S. The company’s proprietary platform uses engineered hyper-immune bovine colostrum to generate pathogen-specific immunoglobulins that remain active in the gastrointestinal tract, supporting a pipeline that includes the ETEC-targeting IMM-124E (commercialized as Travelan), the C. difficile candidate IMM-529, and the IBS-focused product ProIBS distributed under an exclusive agreement in Australia and New Zealand.
Average Trading Volume: 1,287,947
Technical Sentiment Signal: Sell
Current Market Cap: A$13.39M
For an in-depth examination of IMC stock, go to TipRanks’ Overview page.